

Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child?

D. SERRANTI, D. BUONSENSO, M. CECCARELLI, L. GARGIULLO,
O. RANNO, P. VALENTINI

Department of Pediatrics, School of Medicine, Catholic University of the Sacred Heart, Rome (Italy)

Abstract. – Objectives: Pediatric hepatitis C mainly occurs through mother to child transmission, to date. Children usually present a mild disease, but they are not spared from its long-term complications. Thus this infection cannot be underestimated in children and intervention is necessary. Current treatment is based on the administration of pegylated-interferon associated with ribavirin, but few studies evaluated the efficacy and safety of this therapeutic protocol. Moreover, there is still no clarity on who, when and how to treat pediatric patients. This article, based on the information in literature, provides an overview of the main aspects of the disease, with particular attention to treatment.

Methodology and Results: We describe the different treatment options available. About the association peginterferon plus ribavirin, we analyze thirteen non-randomized studies and one trial, found in recent literature. These studies are not directly compared because of differences in age, type of infection (vertical or not), viral genotypes and duration of treatment, between groups enrolled. The overall sustained viral response rate ranges from 28.6% to 81.8%. The rate of treatment success is higher in children infected with genotypes 2 and 3 than with other genotypes. The therapy does not induce severe adverse effects and children present better tolerance to antiviral than adults.

Conclusions: The pharmacological efficacy of peginterferon and ribavirin seems to be proven by data collected in studies cited, but there are different opinions about who, when and how to treat children infected. Thus, further research is needed to define the best management of vertical acquired hepatitis C.

Key Words:

HCV, Mother-to-child, PEG-IFN, Early treatment, Efficacy.

Introduction

Hepatitis C virus (HCV) is a single-stranded RNA virus, classified as a separate genus within the Flaviviridae family. It was cloned first in

1989 and identified as the causative agent of non-A, non-B hepatitis. It was classified in six major genotypes and numerous subtypes; this variability allows the virus to escape host immune surveillance. HCV infects individuals of any age and most of the complications become clinically apparent after a long time, often years. The infection mainly occurs through transfusion of infected blood or through mother to child transmission. Although this liver disease has a significant importance especially in adults, it is a morbid form that cannot be underestimated in children. Even though complications resulting from HCV hepatitis typically do not occur during pediatric age, an early intervention in childhood would prevent, or at least postpone, the unfortunate outcome of the disease.

Epidemiology

HCV infection is a worldwide health problem with a global prevalence of approximately 2% and large regional variations¹. Development of chronic hepatitis and late sequelae (liver cirrhosis and hepatocellular carcinoma) are the most significant consequences of this form of hepatitis.

Several viruses can cause liver disease, but since hepatitis B virus vaccine campaign started in industrialized countries, HCV has become the most significant cause of chronic liver disease of infectious etiology in children².

The highest prevalence of HCV infection is among the 30- to 49-year-old age group³, but this value is not significant in the pediatric population, considering that the major route of HCV transmission is via mother-to-infant transmission.

In fact it's important to know that the majority of children infected with HCV before 1992 acquired infection through transfusion of blood or blood products. After 1992, following the improvements in detection of HCV, transfusion-associated hepatitis C has become extremely rare in countries where adequate facilities for screening blood are available. Therefore, at present most

chronic hepatitis C in children is related to a vertical transmission⁴. This demonstrates that the epidemiological scenario has radically changed in the pediatric population over the last two decades.

It was observed that prevalence of HCV infection in children varies widely by country, ranging from 0% in Japan and 0.4% in Italy to up to 14.5% in Cameroon⁵⁻⁷. More indicative data were collected in an important study conducted in USA, showing that the seroprevalence of HCV antibodies in children ranges between 0.2%, in children aged 6-11 years, and 0.4%, in children aged 12-19 years³.

So, although the infection rate is low, it may potentially result in 50,000 new cases per year⁴, making it a public health problem of great dimensions.

Mother to Child Transmission

The various factors that play a role in vertical transmission are listed in Table I.

Currently, vertical transmission is the most common route of HCV transmission in pediatric population, even though acquiring the infection through blood transfusion or invasive surgical procedures is still possible.

Mother-to-child HCV transmission usually occurs in women with HCV viraemia⁸. In fact vertical infection from mothers negative for HCV RNA is an extremely rare event. However, it is still unclear whether high levels of concentration of viral RNA are associated with an increased risk of transmission.

The risk level is higher in HIV/HCV co-infected mothers than in HIV-negative mothers⁹. It has

been demonstrated that the rate of vertical transmission grow from 3.5% in HIV-negative mothers up to 19.4% in HIV-positive ones¹⁰. There are different hypotheses that would explain this phenomenon. Some Authors sustain that in women coinfecting with HCV and HIV, there is a rise up of HCV viral load, as a result of HIV-mediated immunosuppression¹¹. Other Authors demonstrated that HIV infection facilitates HCV entry and replication in blood cells, favoring child infection¹². Anyway, it was reported that in HCV/HIV-co-infected women, transmission occurred with lower mean HCV viraemia than in non HCV/HIV co-infected women¹³.

History of maternal intravenous drug use is an important predicting factor of perinatal infection associated to peripheral maternal blood mononuclear cell infection by HCV¹⁴. This evidence results to be one of the main risk factor for transmission. Even though the mechanism has not been yet clarified, it has been well demonstrated that lymphocytes may act as an HCV reservoir, playing a key role in the relapse of HCV disease after liver transplantation or after the discontinuation of therapy¹².

It's a curious fact that females are twice as likely to be infected than males, Therefore, child gender may be important for the possibility of transmission¹⁵.

Prolonged rupture of membrane and delivery complications increase the risk of transmission, as well as obstetric procedures and intrapartum exposure to maternal blood infected¹⁶.

The perinatal transmission is not influenced by the mode of delivery. In fact, there are similar infection rates between infants delivered by cae-

Table I. Factors impacting perinatal transmission of Hepatitis C Virus.

Risk factors	Factors predicting the risk	Factors not associated with the risk
Maternal detection of HCV RNA by PCR	Human immunodeficiency virus coinfection	Mode of delivery
Peripheral blood mononuclear cell infection by HCV	History of intravenous drug use	Previous delivering of a child infected perinatally with HCV
Female gender	Maternal disease activity; alanine transaminase concentrations	Breast-feeding
Prolonged rupture of membrane and delivery complications	HCV infection of the father-sexual partner of the mother	Genotype
Obstetric procedures and intrapartum exposure to HCV-infected maternal blood		Mother-child human leukocyte antigen concordance

HCV = hepatitis C virus; RNA = ribonucleic acid; PCR = polymerase chain reaction. The table is adapted from Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. *J Med Virol* 2009; 81: 836-843.

sarean section or vaginally. Furthermore, although HCV RNA may be detected in breast milk and colostrum, breast feeding does not appear to increase the rate of HCV transmission, unless the mother is also HIV positive. Current recommendations are that women with HCV without HIV co-infection can be advised to breast feed⁹.

Diagnosis

Whereas there are no therapeutic interventions to prevent vertical transmission, there would be no indications to screen mothers for HCV. In fact it is important to investigate the presence of risk factors that influence the transmission rate and to test the presence of HCV RNA on maternal blood, because transmission occurs mostly in mothers presenting viraemia.

The diagnosis of perinatal infection is confused by passive transfer of maternal antibodies up to 13 months and occasionally 18 months, and this affects the significance of testing on newborn blood the presence of HCV antibodies¹⁷.

However, our present knowledge indicates that all children born to anti-HCV positive women need to be tested. Anti-HCV testing at 12 and 18 months of age is highly effective for detecting the infection, considering that repeated blood sampling could be invasive for infants. Alternatively, to obtain an earlier diagnosis, PCR tests for HCV-RNA are useful. It is recommended that the first PCR test has to be performed at around 2 months of age and testing has to be repeated at around 6 months of age. Two positive results are highly suggestive of an infection. Although two negative PCR results strongly suggest that the infant is not infected, this needs confirmation by an antibody test performed at, or after, age 1 year¹⁸.

This timing for PCR test is due to its low sensitivity, when executed at birth. In fact, in a study on 547 children, born to HCV infected mothers, it resulted that sensitivity of PCR test is low at birth (22%), but increases to 85% by 6 months; specificity is constant over age at 98%; the positive predictive value of PCR testing rises from 33% at birth to 78% at 9 months of age, while negative predictive value ranges from 96% to 99%¹⁹.

A possible approach to diagnosis is defined in Table II.

Infants born to anti-HCV positive mothers are considered infected when HCV RNA is detected in peripheral blood by PCR in at least two serum

samples during the first year of life and/or when anti-HCV positivity persists beyond 18-24 months of life²⁰.

Resolution is determined by the disappearance of HCV RNA, even though it is fundamental to consider that the disappearance of HCV RNA may be due either to previous transient viraemia phenomenon or to a real infection resolution.


Natural History

Before facing this section, it's of primary importance to know that studies conducted to date on pediatric hepatitis C course generally include both vertical and horizontal infections, patients of any age and often associated with other diseases.

It has been showed that not all infected children will develop chronic infection. In fact clearance of viraemia occurs spontaneously in 19-24% of perinatally infected children in the first 2-3 years of life and the remaining 70-80% develop chronic hepatitis C, as demonstrated in a study on 70 children born to HCV infected woman, enrolled consecutively in five European centers between 1990 and 1999^{21,22}. Children and adolescents who experienced the infection, without virus clearance, usually present a mild disease with normal or only mildly abnormal serum alanine aminotransferase levels²³; children who have vertically acquired the infection are asymptomatic too. Moreover, pediatric patients have less inflammation, fibrosis, and steatosis than adults²⁴, but significant fibrosis and even cirrhosis may develop during childhood and the risk of progressing to end-stage liver disease later in life remains²⁵. In fact, several case reports link chronic HCV infection with the development of hepatocellular carcinoma in adolescents and young adults infected during childhood²⁶.

Finally, other equally important implications characterize chronic course of hepatitis C in children. In fact, although the evolution of the disease does not produce evident signs of illness in pediatric age, it's not possible to ignore the psychological implications of the infection and the difficulties of the family in managing the sick child. HCV infection, in its early stages, does not lead to global impairment in quality of life, or in cognitive, behavioral, emotional disfunctioning in children, but it is associated with higher caregiver stress and strain on the family system, and it may be associated with some cognitive changes in children²⁷.

Table II. Screening and follow-up of infants born to anti-HCV positive mothers.



ALT = alanine aminotransferase; HCV = hepatitis C virus; RNA = ribonucleic acid; PCR = polymerase chain reaction. The flowchart is adapted from Resti M, Bortolotti F, Vajro P, Maggiore G; Committee of Hepatology of the Italian Society of Pediatric Gastroenterology and Hepatology Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis 2003; 35: 453-457.

Treatment

The main aim of therapy is to achieve a sustained viral response (SVR), defined as undetectable serum HCV RNA 24 weeks after treatment cessation.

From the pharmacological point of view three types of approaches have demonstrated effectiveness over the years: first, administration of interferon (IFN) alone, subsequently of IFN with ribavirin and finally the newest protocol, based on the administration of pegylated-interferon (PEG-IFN) with ribavirin. As in the evaluation of natural history, we don't have targeted studies concerning therapy options focused on mother to child acquired infections.

IFN is part of a group of naturally occurring proteins that have antiviral, antiproliferative and immunomodulatory activity. Even though the exact mechanism of action is not well known, this compound is taken up by cells. This reaction leads to a cascade mechanism that inhibits the viral attachment, replication and assembly. In this way the administration of interferon induces a form of resistance against viral infection. This molecule has been the only basis of hepatitis C therapy for a long time.

The efficacy of IFN monotherapy has been evaluated in various randomized and non-randomized studies, often performed in small populations. In an analysis of published trials of interferon monotherapy in children with chronic hepatitis C, an average SVR was observed in 36% of children, with a range from 0% up to 73%²⁸.

In order to increase the rate of response, ribavirin has been associated with the IFN in the HCV infection therapy.

Ribavirin is a synthetic guanosine analogue with activity against several RNA and DNA viruses, including Flaviviridae. It seems to act by interfering with the synthesis of guanosine triphosphate, inhibiting the viral capping of mRNA and inhibiting viral RNA polymerase.

In a randomized control trial a SVR of 59% was observed by this addition²⁹.

However, these therapeutic protocols are no longer used as standard therapies, since the PEG-IFN was produced. So, in adults the approved treatment is based on combination of this new compound and ribavirin. PEG-IFN is synthesized by covalently linking a polyethylene glycol moiety to the IFN. This addition confers an extended serum half-life, compared with the normal IFN, allowing once-weekly dosing. This new pharmacologic property is very important, considering

that resolves the problems due to the IFN administration. In fact, the thrice-weekly dosing of the IFN were not well tolerated by children.

Two kind of PEG-IFN are available: the PEG-IFN α 2b and α 2a. The first one was approved by the US Food and Drug Administration for children aged 3 years and older and the second drug will be approved soon. There is no SVR rate difference between the two formulations in adults³⁰.

Concerning the efficacy of this drug associated to ribavirin, various international studies have been conducted in pediatric patients group. We found 13 non-randomized studies (characteristics of non-randomized studies are summarized in Table III) and 1 randomized control trial published in literature, all including children both with vertical and parenteral acquired infection. There is no study that specifically evaluates only children with vertical acquired infection to date.

In terms of treatment response, a range of SVR values from 28,6%³¹ to 81,8%³² was obtained from non-randomized studies (Table IV and Figure 1). This spread is probably due to different virus genotypes infecting children enrolled. In fact it's necessary to know that the genotype 1, in particular, and 4 are associated with lower response rates to all therapies than are genotype 2 or 3. Thus, the different proportion of genotypes in the groups is the main confounding factor in results interpretation. In those studies that report the subgroups, distinguished by genotypes, it's possible to observe higher rate of SVR related to genotypes 2 and 3³²⁻³⁷.

Sokal et al³³, in their study, compared the group including genotypes 2 and 3 with the group including genotypes 1 and other genotypes, both receiving treatment with PEG-IFN. Early virologic response at week 12 was observed in 83% of the first group patients and in 57% of second and SVR was maintained in 89% of patients in first group and in 57% of second one.

In the only randomized controlled trial of PEG-IFN and ribavirin compared with PEG-IFN and placebo, the efficacy of this association has been demonstrated by the higher SVR rate obtained in children treated with PEG-IFN plus ribavirin than the control group (53% vs 21%). Moreover, the higher SVR rate was related both to a higher end-of-treatment response (no detectable HCV RNA in plasma at the end of therapy) and to a lower relapse rate after stopping therapy than children treated with PEG-IFN and placebo³⁸.

Table III. Non-randomized studies characteristics.

Author/ Year	N.	Characteristics	Age	PEG-IFN	RBV	Weeks	Lost	G1 and others	G2/ G3
Sokal EM/2010	65	Naive	13-17	100 µg/m ²	15 mg/kg/day	-24 for G1 and others -48 for G2/G3	10	47	18
Al Ali J/2010	12	NR	14-17	1.5 mg/kg	15 mg/kg/day	-48	1	12*	0
Wirth S/2010	107	Naive	3-17	60 µg/m ²	15 mg/kg/day	-48 for G1, G4 and G3 with viral load ≥ 600,000 IU/ml			
Tajiri H/2009	37	16 previously treated with IFN	< 30	1.5 mg/kg	15 mg/kg/day	-24 for G2 and G3G3 with viral load < 600,000 IU/ml -48 for G1, -24 for G2/G3	4	22	15
Ghaffar TY/2009	7	6 naïve	8-16	1.5 µg /Kg	15 mg/kg/day	-52	0	6*	0
Jara P/2008	30	75% naïve	3-16	1.0 µg /Kg	15 mg/kg/day	-48 for G1, -24 for G2/G3	3	27	3
Kowala-Praskowska A/2007	23	NR	6-18	1.5 µg /Kg	15 mg/kg/day	-12	0	22	1
Baker RD/2007	10	7 naïve	11-18	1.5 µg /Kg	800 mg/day	-48 for G1, -24 for G2/G3	1	9	1
Pawlowska M/2006	13	4 previously treated with IFN and 9 with IFN plus ribavirin	13,9 (mean age)	1.5 µg /Kg	15 mg/kg/day	-12	1	13	0
Zhang HF/2005	54	inductive treatment with IFN for a week	11,3 (mean age)	104 µg/m ²	15-20 mg/kg/day	-52	0	38	NR
Wirth S/2005	62	NR	2-17	1.5 µg /Kg	15 mg/kg/day	-48	1	48	13
Shuzewski W/2005	10	NR	NR	NR	NR	NR	0	10**	0
Kowala-Praskowska A/2005	20	NR	NR	NR	NR	-48		20**	0

*In the studies of Al Ali, J and Ghaffar TY there were only genotype 4 patients; **In Sluzewski W and Kowala-Praskowska studies there were only genotype 1 patients.

Table IV. Efficacy parameters evaluated in non-randomized studies.

Author/Year	EVR (%)	SVR (%)	G1 and others SVR (%)	G2/G3 SVR (%)
Sokal EM/2010	42 (64.6)	43 (66.1)	27 (57)	16 (89)
Al Ali J/2010	NR	9 (75)	9 (75)*	
Wirth S/2010	NR	70 (65)	42 (54.5)	28 (93)
Tajiri H/2009	10 (30.3)	27 (81.8)	16 (80)	11 (84.6)
Ghaffar TY/2009	NR	2 (28.6)	2 (28.6)*	
Jara P/2008	19 (72)	15 (50)	12 (44.4)	3 (100)
Kowala-Piaskowska A/2007	15 (65.3)	NR	NR	NR
Baker RD/2007	NR	3 (33.3)	2 (22.2)	1 (100)
Pawlowska M/2006	6 (50)	NR	NR	NR
Zhang HF/2005	42 (87.5)	NR	NR	NR
Wirth S/2005	NR	35 (57.3)	23 (47.9)	13 (100)
Sluzewski W/2005**		ETR 8 (80)		
Kowala-Piaskowska A/2005**		ETR 17 (85)		

*In the studies of Al Ali J and Ghaffar TY there were only genotype 4 patients; **In these studies only ETR was reported; EVR is defined as undetectable HCV RNA in serum or >2 log10 decrease in HCV RNA compared with baseline values; SVR is defined as a negative HCV RNA at least 24 weeks after cessation of therapy; ETR is defined as negative HCV RNA at the end of treatment.

The role of genotype has been also confirmed in this study: 47% of SVR was achieved in children infected by genotype 1 virus and 80% of SVR in those infected by the other genotypes³⁸. These results are similar to those obtained in previous non-randomized studies and give further support to the choice of using this therapy in pediatric hepatitis C.

How long to administer these drugs is still subject of debate. Even though 24 weeks of PEG-IFN plus ribavirin are effective for genotypes 2 and 3 in adults³⁹, the duration of therapy recommended for all children is 48 weeks for all genotypes. The evaluation of a shorter duration of treatment is still ongoing and some pediatric studies³³ have already shown excellent re-




Figure 1. SVR total and by genotype of PEG-IFN/ribavirin therapy in non-randomized studies. We included in this graphic only the studies that reported the SVR rates. All patients in the Al Ali J and Ghaffar studies were genotype 4.

sults with 24 weeks of treatment for genotypes 2 and 3.

Furthermore, when treatment with PEG-IFN and ribavirin is started, possible side effects have to be considered. Flu-like and gastrointestinal symptoms arise quite often, similarly to side effects following administration of IFN. As we could see in all studies mentioned³³⁻³⁸, these symptoms occurred in most children treated. Moreover, therapy leads to significant decline in total white blood cell count, absolute neutrophil count and hemoglobin, which generally return to baseline at the end of treatment³⁸. These adverse events are important, but they do not involve the treatment discontinuation. In any case when they occur the dose of PEG-INF and/or ribavirin should be reduced.

It's important to know that a better compensatory bone marrow function was observed in children aged 3-11 years, demonstrating a better tolerance of youngest children to these drugs³⁴.

Body height and weight loss are common during the treatment phase. However, a weight gain after the end of therapy is generally observed along with an improved growth velocity, even though these children remain slightly below the median for their population³⁴.

Mild or moderate psychiatric disorders may also occur, but similarly to the previous problems, they do not generally cause changes in therapy. These symptoms could appear as mild anxiety, irritability, insomnia, agitation, restlessness, mood swings, behavioral changes, affect lability and depression. It's an extremely rare occurrence that these conditions necessitate treatment discontinuation or antidepressant therapy³³⁻³⁸.

In a few cases hypothyroidism, hyperthyroidism and related TSH abnormalities may appear, but permanent endocrinological disorders are uncommon.

New onset juvenile diabetes mellitus is extremely rare.

To Treat or Not to Treat?

While studies and research on antiviral therapy are advancing, there is still no clarity about what children should be treated with and how to perform the therapy. In fact, concerning chronic HCV hepatitis, there are many opinions both in support and against the administration of antiviral drugs during pediatric age.

Although the US Food and Drug has approved the administration of PEG-IFN for children aged 3 years or older, the hesitations on the use of this

compound associated to ribavirin in children remain. The studies we cited seems to prove the pharmacological efficacy of this treatment protocol, but this is not the only aspect that needs to be considered, in order to choose whether to treat or not. Moreover, it is even more difficult to answer questions about who, when and how to treat in the specific case of vertically acquired HCV infection. Studies focused on this particular population have not yet been designed, though at present this is the major route of transmission. So, even considering results supporting the efficacy of PEG-INF plus ribavirin, it is difficult to establish precise treatment guidelines.

In fact, HCV hepatitis is a mild disease that is not expressed in its entirety during pediatric age, thus infected children are usually asymptomatic and some of them have the possibility of a spontaneous resolution^{22,23}. Thereby, considerations about the natural history of disease make the choice of whether to treat or not rather very hard.

Risk to develop severe liver disease could be the ideal criterion for selecting individuals to treat.

In such an ideal approach, patients who expected to have a benign course would be spared treatment and thereby, avert potential medication-related adverse effects⁴⁰. However, it's necessary to consider the long-term complications of the disease, which will occur with high probability in adulthood; the psychological component related to the long term course of hepatitis C should also be taken into account. In fact, deferring the therapy to adulthood could pose significant psychological implications, due to the possible social exclusion of the child; being considered "infected" would be unable to develop social relationships in his environment²⁷. Management, continuous monitoring and procedures used to evaluate the course of hepatitis may become sources of great stress for the child and his family.

Choices on pediatric therapy may be also influenced by the economic burden of managing these patients, which can become substantial in the future. An evaluation from this point of view has been made in 2006, where medical costs associated with diagnostic procedures and care of children with chronic HCV infection over the next 10 years were evaluated⁴¹. A charge from \$168 up to \$404 million was estimated in USA, that may be considered large enough to justify a therapeutic intervention in children affected.

Anyway, it needs to be highlighted that therapy generally gives better results in children as ev-

identified by the studies already mentioned. In addition to the high rate of success, demonstrated by the SVR rate, children present an excellent tolerance to treatment with fewer side effects determined by drugs. In particular an optimal compensatory bone marrow function was observed in children aged 3-11 years³⁴, allowing them to have a good response to the decline in total white blood cell count and absolute neutrophil count, due to antiviral administration.

For these reasons, initiating therapy before adolescence or adulthood offers higher efficacy, better compliance, eradication before initiation of high risk behaviors (that may transmit infection to others), economic advantages, and improved quality of life with less long-term anxiety, fewer medical visits for observation, and less testing for disease progression⁴².

Given that there seems to be an inverse relation between age of initiation of treatment and chances of success, a prospective for the future could be starting therapy early before three years of age. Mother-to-child transmitted hepatitis C, in fact, could be considered as a recent infection at the time of birth, since it occurred in utero or during delivery.

Studies conducted in adults show that intervention during the acute phase of the infection are more effective. Treatment started within 12 weeks from diagnosis causes, in fact, an higher rate of viral clearance, compared with no treatment⁴³.

A question still remains unsolved: should an early treatment be evaluated in HCV-vertical infected children?

References

- 1) SHEPARD CW, FINELLI L, ALTER MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005; 5: 558-567.
- 2) SLOWIK MK, JHAVERI R. Hepatitis B and C viruses in infants and young children. *Semin Pediatr Infect Dis* 2005; 16: 296-305.
- 3) ALTER MJ, KRUSZON-MORAN D, NAINAN OV, MCQUILLAN GM, GAO F, MOYER LA, KASLOW RA, MARGOLIS HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999; 341: 556-562.
- 4) YEUNG LT, KING SM, ROBERTS EA. Mother-to-infant transmission of hepatitis C virus. *Hepatology* 2001; 34: 223-229.
- 5) GESSONI G, MANONI F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. *Eur J Med* 1993; 2: 79-82.
- 6) NGATCHU T, STROFFOLINI T, RAPICETTA M, CHIONNE P, LANTUM D, CHIARAMONTE M. Seroprevalence of anti-HCV in an urban child population: a pilot survey in a developing area, Cameroon. *J Trop Med Hyg* 1992; 95: 57-61.
- 7) TANAKA E, KIYOSAWA K, SODEYAMA T, HAYATA T, OHIKE Y, NAKANO Y, YOSHIZAWA K, FURUTA S, WATANABE Y, WATANABE J, et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. *Am J Trop Med Hyg* 1992; 46: 460-464.
- 8) RESTI M, AZZARI C, MANNELLI F, MORIONDO M, NOVEMBRE E, DE MARTINO M, VIERUCCI A. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. *Tuscany Study Group on Hepatitis C Virus Infection. Br Med J* 1998 15; 317(7156): 437-441.
- 9) EUROPEAN PAEDIATRIC HEPATITIS C VIRUS NETWORK. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. *European Paediatric Hepatitis C Virus Network. BJOG* 2001; 108: 371-377.
- 10) ROBERTS EA, YEUNG L. Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 2002; 36(5 Suppl 1): S106-113.
- 11) ZANETTI AR, TANZI E, PACCAGNINI S, PRINCIPI N, PIZZOCCO G, CACCAMO ML, D'AMICO E, CAMBIÈ G, VECCHI L. Mother-to-infant transmission of hepatitis C virus. *Lombardy Study Group on Vertical HCV Transmission. Lancet* 1995; 345(8945): 289-291.
- 12) AZZARI C, RESTI M, MORIONDO M, FERRARI R, LIONETTI P, VIERUCCI A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. *Blood* 2000; 96: 2045-2048.
- 13) MAST EE, HWANG LY, SETO DS, NOLTE FS, NAINAN OV, WURTZEL H, ALTER MJ. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis* 2005; 192: 1880-1889.
- 14) AZZARI C, MORIONDO M, INDOLFI G, BETTI L, GAMBINERI E, DE MARTINO M, RESTI M. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. *J Med Virol* 2008; 80: 65-71.
- 15) PEMBREY L, NEWELL ML, TOVO PA; EUROPEAN PAEDIATRIC HEPATITIS C VIRUS NETWORK. Age-related lymphocyte and neutrophil levels in children of hepatitis C-infected women. *Pediatr Infect Dis J* 2008; 27: 800-807.
- 16) STEININGER C, KUNDI M, JATZKO G, KISS H, LISCHKA A, HOLZMANN H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum

- infantile exposure to maternal blood. *J Infect Dis* 2003; 187: 345-351.
- 17) DUNN DT, GIBB DM, HEALY M, GOODALL RL, BUTLER K, CAFFERKEY M, NEAVE P. Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection. *Pediatr Infect Dis J* 2001; 20: 715-716.
 - 18) PEMBREY L, NEWELL ML, TOVO PA; EPHN COLLABORATORS. The management of HCV infected pregnant women and their children European paediatric HCV network. *J Hepatol* 2005; 43: 515-525.
 - 19) POLYWKA S, PEMBREY L, TOVO PA, NEWELL ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. *J Med Virol* 2006; 78: 305-310.
 - 20) RESTI M, BORTOLOTTI F, VAJRO P, MAGGIORE G; COMMITTEE OF HEPATOLOGY OF THE ITALIAN SOCIETY OF PEDIATRIC GASTROENTEROLOGY AND HEPATOLOGY. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. *Dig Liver Dis* 2003; 35: 453-457.
 - 21) RESTI M, JARA P, HIERRO L, AZZARI C, GIACCHINO R, ZUIN G, ZANCAN L, PEDDITZI S, BORTOLOTTI F. Clinical features and progression of perinatally acquired hepatitis C virus infection. *J Med Virol* 2003; 70: 373-377.
 - 22) EUROPEAN PAEDIATRIC HEPATITIS C VIRUS NETWORK. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. *Clin Infect Dis* 2005; 41: 45-51.
 - 23) IORIO R, GIANNATTASIO A, SEPE A, TERRACCIANO LM, VECCHIONE R, VEGNENTE A. Chronic hepatitis C in childhood: an 18-year experience. *Clin Infect Dis* 2005; 41: 1431-1437.
 - 24) GUIDO M, BORTOLOTTI F, LEANDRO G, JARA P, HIERRO L, LARRAURI J, BARBERA C, GIACCHINO R, ZANCAN L, BALLI F, CRIVELLARO C, CRISTINA E, PUCCI A, RUGGE M. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? *Am J Gastroenterol* 2003; 98: 660-663.
 - 25) GOODMAN ZD, MAKHLOUF HR, LIU L, BALISTRERI W, GONZALEZ-PERALTA RP, HABER B, JONAS MM, MOHAN P, MOLLESTON JP, MURRAY KF, NARKEVICZ MR, ROSENTHAL P, SMITH LJ, ROBUCK PR, SCHWARZ KB. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. *Hepatology* 2008; 47: 836-843.
 - 26) GONZÁLEZ-PERALTA RP, LANGHAM MR JR, ANDRES JM, MOHAN P, COLOMBANI PM, ALFORD MK, SCHWARZ KB. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. *J Pediatr Gastroenterol Nutr* 2009; 48: 630-635.
 - 27) RODRIGUE JR, BALISTRERI W, HABER B, JONAS MM, MOHAN P, MOLLESTON JP, MURRAY KF, NARKEVICZ MR, ROSENTHAL P, SMITH LJ, SCHWARZ KB, ROBUCK P, BARTON B, GONZÁLEZ-PERALTA RP. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. *J Pediatr Gastroenterol Nutr* 2009; 48: 341-347.
 - 28) JACOBSON KR, MURRAY K, ZELLOS A, SCHWARZ KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. *J Pediatr Gastroenterol Nutr* 2002; 34: 52-58.
 - 29) FRIED MW, PETER J, HOOTS K, GAGLIO PJ, TALBUT D, DAVIS PC, KEY NS, WHITE GC, LINDBLAD L, RICKLES FR, ABSHIRE TC. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. *Hepatology* 2002; 36(4 Pt 1): 967-972.
 - 30) MCHUTCHISON JG, LAWITZ EJ, SHIFFMAN ML, MUIR AJ, GALLER GW, MCCONE J, NYBERG LM, LEE WM, GHALIB RH, SCHIFF ER, GALATI JS, BACON BR, DAVIS MN, MUKHOPADHYAY P, KOURY K, NOVIELLO S, PEDICONE LD, BRASS CA, ALBRECHT JK, SULKOWSKI MS; IDEAL STUDY TEAM. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 2009; 361: 580-593.
 - 31) GHAFFAR TY, EL NAGHY S, EL SEBAIE H, EL MONAIERI M, GHAFFAR AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. *Indian J Pediatr* 2009; 76: 895-898.
 - 32) TAJIRI H, INUI A, KIYOHARA Y, SUZUKI M, KAGIMOTO S, ETANI Y, SHIMIZU T, FUJISAWA T. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. *Eur J Gastroenterol Hepatol* 2009; 21: 1256-1260.
 - 33) SOKAL EM, BOURGOIS A, STÉPHENNE X, SILVEIRA T, PORTA G, GARDOVSKA D, FISCHLER B, KELLY D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. *J Hepatol* 2010; 52: 827-831.
 - 34) WIRTH S, RIBES-KONINCKX C, CALZADO MA, BORTOLOTTI F, ZANCAN L, JARA P, SHELTON M, KERKAR N, GALOPPO M, PEDREIRA A, RODRIGUEZ-BAEZ N, CIOCCA M, LACHAUX A, LACAILE F, LANG T, KULLMER U, HUBER WD, GONZALEZ T, POLLACK H, ALONSO E, BROUE P, RAMAKRISHNA J, NEIGUT D, VALLE-SEGARRA AD, HUNTER B, GOODMAN Z, XU CR, ZHENG H, NOVIELLO S, SNIUKIENE V, BRASS C, ALBRECHT JK. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. *J Hepatol* 2010; 52: 501-507.
 - 35) JARA P, HIERRO L, DE LA VEGA A, DÍAZ C, CAMARENA C, FRAUCA E, MIÑOS-BARTOLO G, DIEZ-DORADO R, DE GUEVARA CL, LARRAURI J, RUEDA M. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. *Pediatr Infect Dis J* 2008; 27: 142-148.
 - 36) BAKER RD, DEE D, BAKER SS. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. *J Clin Gastroenterol* 2007; 41: 111-114.
 - 37) WIRTH S, PIEPER-BOUSTANI H, LANG T, BALLAUFF A, KULLMER U, GERNER P, WINTERMEYER P, JENKE A. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. *Hepatology* 2005; 41: 1013-1018.

- 38) SCHWARZ KB, GONZALEZ-PERALTA RP, MURRAY KF, MOLLESTON JP, HABER BA, JONAS MM, ROSENTHAL P, MOHAN P, BALISTRERI WF, NARKEWICZ MR, SMITH L, LOBRITTO SJ, ROSSI S, VALSAMAKIS A, GOODMAN Z, ROBUCK PR, BARTON BA; PEDS-C CLINICAL RESEARCH NETWORK. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents chronic hepatitis C. *Gastroenterology* 2010; Oct 28. [Epub ahead of print].
- 39) HADZIYANNIS SJ, SETTE H JR, MORGAN TR, BALAN V, DIAGO M, MARCELLIN P, RAMADORI G, BODENHEIMER H JR, BERNSTEIN D, RIZZETTO M, ZEUZEM S, POCKROS PJ, LIN A, ACKRILL AM; PEGASYS INTERNATIONAL STUDY GROUP. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140: 346-355.
- 40) GONZÁLEZ-PERALTA RP. Treatment of chronic hepatitis C in children. *Pediatr Transplant* 2004; 8: 639-643.
- 41) JHAVERI R, GRANT W, KAUF TL, MCHUTCHISON J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. *J Pediatr* 2006; 148: 353-358.
- 42) KARNSAKUL W, ALFORD MK, SCHWARZ KB. Managing pediatric hepatitis C: current and emerging treatment options. *Ther Clin Risk Manag* 2009; 5: 651-660.
- 43) COREY KE, MENDEZ-NAVARRO J, GOROSPE EC, ZHENG H, CHUNG RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. *J Viral Hepat* 2010; 17: 201-207.